Recursion Pharmaceuticals, Inc. (RXRX) Financial Statements
Recursion Pharmaceuticals, Inc. (RXRX) reported trailing twelve-month revenue of $54.9M (down 15.1% year on year) and net income of -$518.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$352.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26. Results for the next quarter were released 15 Oct; these figures move once the 10-Q is filed.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.01 | 0.04 | 0.04 | 0.06 | 0.07 | 0.05 | |
| Gross profit | — | -0.01 | 0.00 | 0.01 | 0.00 | 0.00 | |
| Research & development | 0.14 | 0.16 | 0.24 | 0.31 | 0.48 | 0.39 | |
| Operating income | -0.18 | -0.25 | -0.35 | -0.48 | -0.65 | -0.54 | |
| Pre-tax income | -0.19 | -0.24 | -0.33 | -0.46 | -0.64 | -0.52 | |
| Income tax | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 | |
| Net income | -0.19 | -0.24 | -0.33 | -0.46 | -0.64 | -0.52 | |
| Diluted EPS ($) | -1.49 | -1.36 | -1.58 | -1.69 | -1.44 | -0.97 | |
| Diluted shares (bn) | 0.125 | 0.176 | 0.208 | 0.274 | 0.447 | — |
USD billions · SEC XBRL
Recursion Pharmaceuticals, Inc. — questions
- What is Recursion Pharmaceuticals, Inc.'s revenue?
- $54.9M over the twelve months to 2026-06-30, down 15.1% year on year, from its 10-Q and 10-K filings.
- What is Recursion Pharmaceuticals, Inc.'s net income?
- -$518.9M over the twelve months to 2026-06-30.
- What is Recursion Pharmaceuticals, Inc.'s free cash flow?
- -$352.3M over the twelve months to 2026-06-30.
- What are Recursion Pharmaceuticals, Inc.'s diluted earnings per share?
- $-0.97 over the twelve months to 2026-06-30.
Every figure on this page comes from Recursion Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.